US 11,944,706 B2
Hybridosomes, compositions comprising the same, processes for their production and uses thereof
Joel de Beer, Zollikon (CH)
Assigned to Anjarium Biosciences AG, Schlieren (CH)
Filed by ANJARIUM BIOSCIENCES AG, Schlieren (CH)
Filed on Sep. 12, 2022, as Appl. No. 17/942,617.
Application 17/942,617 is a continuation of application No. 16/732,567, filed on Jan. 2, 2020, granted, now 11,484,500.
Application 16/732,567 is a continuation of application No. 15/112,180, granted, now 10,561,610, issued on Feb. 18, 2020, previously published as PCT/IB2015/050436, filed on Jan. 20, 2015.
Claims priority of provisional application 61/929,559, filed on Jan. 21, 2014.
Prior Publication US 2023/0181467 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 47/69 (2017.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); C12N 15/88 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 9/1271 (2013.01); A61K 9/1277 (2013.01); A61K 47/6911 (2017.08); A61K 47/6913 (2017.08); C07K 16/2896 (2013.01); C12N 15/113 (2013.01); C12N 15/88 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); Y02A 50/30 (2018.01)] 12 Claims
 
1. A hybridosome comprising a therapeutic agent encapsulated by a membrane of the hybridosome; wherein the membrane of the hybridosome comprises:
a. elements of a membrane of a first vesicle, wherein the elements of a membrane of the first vesicle comprise a fusogenic, ionizable cationic lipid, wherein said fusogenic, ionizable cationic lipid has at least one protonatable or deprotonatable group, such that the lipid is positively charged at a pH and neutral above the pH, and wherein said first vesicle has been produced in vitro such that the fusogenic, ionizable cationic lipid is present at a molar concentration of at least 30% of total lipid of the first vesicle; and
b. elements of a lipid bilayer of a second vesicle, wherein said second vesicle has been produced in vivo and is released into the extracellular environment.